🇺🇸

Corporate Governance

· daily

US Executive Compensation Proxy SEC Filings — May 13, 2026

Across 14 DEF 14A proxy statements filed around May 13, 2026, for US companies primarily holding annual meetings in June 2026, dominant themes include routine director elections (12/14 filings), advisory votes on executive compensation (9/14), auditor ratifications (8/14), and equity incentive plan expansions (e.g., BOX +7.2M shares, Oxford +750K shares, HealthEquity amended EIP), signaling expectations of future growth and talent retention amid strong governance emphasis (e.g., BOX 7/8 independent directors, Kroger all but CEO/Chair independent). Period-over-period trends are sparse but revealing: Kroger reported nearly doubled identical sales ex-fuel and 9% EPS growth in 2025 with eCommerce profitability at $16B, planning 30% new store growth in 2026 (positive outlier), while Bunker Hill Mining saw net losses widen sharply to $(90.4M) in 2025 from $(29.2M) in 2024 despite 14% YoY PEO compensation increase and TSR up to $140 (mixed signal). Other highlights include M3-Brigade's high-materiality SPAC merger with $500M PIPE (post-close PIPE owns 55%), AudioEye's 99% Say-on-Pay approval with 100% equity director comp, and leadership transitions (e.g., Perma-Pipe 3 resignations, Oxford director retirement at 72). Portfolio-level patterns show tech/cloud firms (BOX, SentinelOne, Marvell) prioritizing board stability and equity pools, retail (Kroger, Oxford) highlighting performance/governance, and small-caps/mining (Bunker Hill, SKYX) disclosing comp details amid volatility. Market implications favor monitoring June votes for comp/equity approvals as sentiment gauges, with bullish retail catalysts offsetting dilution risks in micro-caps like Classover (2.5B Class B authorization). No widespread insider selling noted, but equity-heavy comp (e.g., AudioEye RSU holdings up to 102K vested) indicates alignment.

14 high priority 14 total filings
· daily

US Executive Officer Management Changes SEC — May 13, 2026

Across 41 filings on USA Executive & Director Changes from May 13, 2026, the dominant theme is orderly leadership transitions, with 12 CEO/CFO/COO changes (e.g., HF Sinclair CFO terminated after leave, Power Solutions CEO resignation to interim CFO, Rent the Runway CEO to interim), 15+ successful annual meetings approving directors (90-99% support), comp plans, and auditors, signaling strong shareholder alignment. Financial reporters show mixed period trends: Doximity FY2026 revenue +13% YoY to $644.9M but Q4 net income -69% to $19.1M; Jack in the Box Q2 revenue -4.3% YoY, SSS -3.8%, margins -320 bps; Tango Q1 net loss +14% to $45.5M despite cash runway to 2028; Zenas Q1 net loss widened to $81M on +73% R&D. Capital allocation remains shareholder-friendly with Hanover's $700M buyback (replacing $63M remainder), Coeur's inaugural $0.02/share dividend (record May 22), and multiple LTIPs approved (e.g., MDU +6.5M shares). Positive sentiments dominate (22/41 positive, 10 neutral), with biotech/pharma showing clinical catalysts (Zenas BLA Q2 2026) amid leadership refreshes, implying sector rotation opportunities but watch CFO turnover (6 cases) for finance risks.

41 high priority 41 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 13, 2026

Across 41 SEC filings on USA Board Room Changes from May 13, 2026, the dominant theme is high C-suite and board turnover, with 12 CEO/CFO/president departures or transitions (e.g., HF Sinclair CFO termination, Power Solutions CEO resignation, Rent the Runway CEO step-down) amid neutral-to-negative sentiment, signaling potential instability in energy, pharma, and tech sectors. Annual shareholder meetings (15 filings) overwhelmingly passed director elections, auditor ratifications, and equity plans with 90-99% support (e.g., Vertex 94-99%, MDU >90%), reinforcing governance stability. Period-over-period trends show mixed financials: revenue growth in Doximity (+13% FY2026 YoY to $644.9M) and cash runway extensions (Tango to 2028, Zenas to Q2 2029), but margin compression in consumer names (Jack in the Box Restaurant-Level Margin -320 bps YoY to 16.4%) and widening losses in biopharma (Tango net loss +14% to $45.5M, Zenas +141% to $81M). Capital allocation leans bullish with Hanover's $700M buyback authorization (+$637M vs prior remainder), Coeur Mining's inaugural $0.02/share dividend, and LTIP expansions (e.g., MDU +6.56M shares). Forward-looking catalysts cluster in pharma (e.g., Zenas BLA Q2 2026, Tango data readouts 2026), while leadership promotions signal continuity (e.g., Toll Brothers EVP to President). Portfolio implication: Favor stable boards with buybacks/dividends; avoid high-turnover firms until interim stability proven.

41 high priority 41 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 12, 2026

Across 12 DEF 14A filings dated May 12, 2026, a dominant theme is clustered June 2026 shareholder meetings (10/12 between June 2-25) for director elections (11/12), auditor ratifications (9/12), say-on-pay votes (4/12), and advisory agreement approvals amid control changes or M&A (5/12 funds/ETFs). Period-over-period trends reveal stark contrasts: NVIDIA's explosive FY2026 revenue +65% YoY to $215.9B and EPS +67% to $4.90 outpace peers, while CarMax EPS plunged -47.7% YoY to $1.68 amid sales declines and impairments, Apogee sales edged +3% YoY but op margin contracted -270 bps to 6.0%, and funds show no financial declines but advisor disruptions. Mixed sentiment prevails (4/12 mixed), with high materiality in growth outliers (NVIDIA, CarMax 9/10) and fund transitions (MFS, Tavia 9/10). No insider trading or capital allocation shifts noted across filings, but director ownership at Dyadic (20.9%) signals alignment. Market implications include governance catalysts for volatility, potential continuity post-approvals boosting stability in funds/tech, and relative outperformance opportunities in high-growth names like NVDA versus cyclical decliners like KMX/APOG. Portfolio-level pattern: Margin compression in 3/4 detailed financials (avg -150 bps) despite uneven revenue growth, highlighting cost pressures amid transitions.

12 high priority 12 total filings
· daily

US Executive Officer Management Changes SEC — May 12, 2026

Across 50 filings in the USA Executive & Director Changes stream (43 new), the dominant theme is routine annual shareholder meetings (20+ companies) approving directors, equity incentive plans (share increases averaging 4-6M shares), say-on-pay, and auditors with strong majorities, signaling stable governance amid minor oppositions (e.g., 20% against Piedmont's plan). Executive transitions dominate (25+ cases), mostly neutral/positive retirements/appointments (e.g., new COOs/CFOs/CEOs at Standard Motor, Laser Photonics, Eagle Bancorp) with seamless handovers, though negative separations (HF Sinclair CEO/CFO) and distress (Bitcoin Depot) stand out. Period trends show robust revenue growth in growth sectors (SOLV +66% YoY Q1 rev/$93M EBITDA +174%; Arteris +39% YoY; Nextpower FY26 +20% to $3.56B; TransAct +10% YoY) but widening losses (C3.ai FY26 op loss $(217.8)M vs $(88.1)M; Bitcoin -49% YoY rev). Capital allocation favors repurchases (Progressive 25M shares, TransAct $3M) and dividends (Progressive $0.10/share July 10), while M&A (SOLV $45M acquisition) and financings (Achieve $354M) support growth. Forward-looking catalysts include FDA dates (Achieve June 20), retirements (Arteris CFO Aug 31), and guidance raises (SOLV EBITDA $435-455M FY26), implying portfolio-level stability but sector-specific alpha in tech/energy transitions.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 12, 2026

Across 50 SEC filings on USA Board Room Changes from May 12, 2026, dominant themes include orderly executive transitions (12 CEO/CFO changes, mostly retirements/appointments with successors), annual shareholder meetings (20+ with director elections and equity plan approvals, averaging 90%+ support but 20% opposition on share increases), and board expansions with industry veterans (e.g., ex-TI, Caterpillar execs). Period-over-period trends show revenue acceleration in 7 reporters (avg +37% YoY: SOLV +66%, Arteris +39%, Nextpower +20%), but mixed profitability (SOLV EBITDA +174%, yet net losses widened in HF Sinclair, Bitcoin Depot -49% YoY rev). Guidance raised in SOLV ($435-455M EBITDA), Arteris ($91-95M rev), TransAct ($1-1.75M EBITDA), signaling growth conviction amid transitions. Capital allocation favors buybacks (TransAct $3M, Progressive 25M shares) and dividends (Progressive $0.10/share). Portfolio-level patterns: Financials/healthcare see high turnover (8 changes), tech/energy mixed financials with positive board sentiment (avg materiality 7/10). Implications: Bullish stability in most changes boosts confidence; monitor financial reporters for Q2 catalysts amid 5 negative departures.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 11, 2026

Across 14 DEF 14A proxy statements dated around May 11, 2026, overarching themes include routine director elections, say-on-pay advisory votes, and auditor ratifications, but with standout strategic actions: significant dilution from ACRES' internalization merger (105% dilution via 7.5M new shares), Coursera's Udemy merger boosting scale to $1.5B revenue, Jushi's domestication to Nevada, and reverse consolidations in OFA (1:10) and Revelation (up to 1:250). Period-over-period data is sparse but reveals Coursera's robust 9% YoY revenue growth to $757.5M and record $78.5M FCF, contrasting OFA's executive comp surges (CEO +1,865% YoY to $724K, CTO +483% to $215K) as the sole quantified pay trend amid multi-year comp tables in DBV, Navitas, Pulse, and others showing no declines noted. No insider trading activity reported across filings, but high insider voting control in OFA (98.68%) raises governance flags. Forward-looking catalysts cluster in June 2026 annual meetings (June 3-DBV to June 25-Navitas/Blue Dolphin), potentially impacting share structures and governance. Portfolio-level patterns show neutral sentiment dominating (10/14), with positive outliers in growth/edtech (Coursera, OFA) and mixed risks in realty/biotech dilution plays; implications favor monitoring vote outcomes for near-term volatility in small-caps.

14 high priority 14 total filings
· daily

US Executive Officer Management Changes SEC — May 11, 2026

Across 38 filings on US executive and director changes from May 11, 2026, a dominant theme is high turnover in finance roles (CFO/CAO resignations in 7 companies: Sonoco, Nature's Sunshine, Equinix, Ecolab, AnaptysBio interim, Koppers interim transition), often neutral with no disagreements cited, signaling routine transitions amid stabilizing operations. Positive appointments of experienced leaders in tech/EV/mining (SolarEdge CFO, PagerDuty CEO, Faraday Future founder CEO, Hycroft Exec Chair) and promotions (Uber Chief Corporate Affairs, Midland States CFO) outnumber departures, with 12/38 filings showing positive sentiment tied to growth strategies like Faraday's 68 EAI robots at positive margins targeting 1,000 in 2026. Annual meetings (UPS, Alcoa, Charles River, CarParts, Ecolab) overwhelmingly approved directors/comp plans (e.g., UPS 90%+ FOR on comp), but some opposition (CarParts Nanxi Liu 44% withheld, Ecolab Zillmer 50M against) hints at governance scrutiny. Spin-off catalysts like Resideo's ADI ($4.8B rev, 6.6% EBITDA margin) mid-Q3/Q4 2026 unlock value, while change-of-control at Byrn Inc (84.7% voting power shift) flags M&A risks. No broad YoY/QoQ deteriorations, but mixed metrics (ADI $261M net loss) and reaffirmed guidance (PagerDuty FY2027 $488.5-496.5M rev) suggest sector resilience; portfolio implication: overweight firms with internal promotions and catalysts vs underweight high-turnover finance roles.

38 high priority 38 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 11, 2026

Across 38 US SEC filings on board room changes from May 11, 2026, a surge in C-suite transitions dominates, with 14 CFO/CAO changes (e.g., SolarEdge, Nature’s Sunshine, Koppers), 8 CEO/Chair shifts (e.g., Faraday Future, PagerDuty, American Cannabis), and numerous board resignations/appointments, signaling strategic realignments amid AI/EV growth and spin-offs. Annual meetings (e.g., UPS, Alcoa, Charles River) showed overwhelming approvals for directors, compensation plans, and auditors (avg 90%+ FOR votes), with minor opposition in select cases like CarParts.com (25% withheld for one director). Positive forward-looking catalysts include Faraday Future's 68 EAI robots shipped (positive gross margins, targeting 200 by June 2026 end, 1,000+ cumulative), Resideo's ADI spin-off (Q3-Q4 2026, $4.8B FY2025 rev, 6.6% EBITDA margin), and PagerDuty's reaffirmed FY2027 guidance ($488.5-496.5M rev). Neutral sentiment prevails (60% of filings), but positive tones in tech/EV/mining (e.g., Hycroft, Uber) contrast mixed in retail/transport; no widespread YoY declines noted, though ADI's $261M net loss flags spin-off risks. Portfolio implication: Leadership refreshes enhance conviction in growth sectors, but monitor interim gaps and proxy contests (e.g., Victoria's Secret). Overall, bullish for AI/robotics plays, neutral stability elsewhere.

38 high priority 38 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 08, 2026

Across 15 DEF 14A proxy statements filed around May 8, 2026, the dominant theme is routine annual shareholder meetings in June 2026 focused on director elections, auditor ratifications, and advisory votes on executive compensation, with 12/15 featuring board elections or renewals signaling governance continuity. Period-over-period financial trends are sparse but highlight resilience in apparel (PVH Corp revenue growth amid macro challenges, 8.8% non-GAAP margins despite -80 bps tariff hit, $560M shareholder returns) contrasted by edtech weakness (Skillsoft FY2026 revenue -3% YoY to $513M, net loss widened to $140M). Mixed sentiments prevail in 3 filings, driven by SPAC extension risks (Rising Dragon high prior redemptions of 5.7M shares at $10.63 vs $7.63 market price) and fund strategy shifts (John Hancock non-diversified status increases concentration risk). Capital allocation leans positive with PVH's repurchases and Criteo's buyback authorizations, while forward-looking catalysts cluster in mid-June meetings for potential equity plan approvals and governance changes like board declassifications (NRC, nCino). No widespread insider trading activity noted, but sponsor deposits in Rising Dragon indicate management conviction. Overall, low materiality (avg 6.5/10) suggests stable but unexciting proxy season, with alpha in governance upgrades and SPAC extension outcomes.

15 high priority 15 total filings
· daily

US Executive Officer Management Changes SEC — May 08, 2026

Across 50 filings from May 8, 2026, focused on USA executive and director changes, the dominant theme is annual shareholder meetings (20+ companies) with strong approvals for director elections (avg 90%+ FOR votes), say-on-pay (avg 85%+ approval), and equity plans, signaling robust governance alignment amid stable financial health implied by auditor ratifications. Notable cluster of CFO resignations and appointments at Franklin Templeton ETF sponsors (6 filings: Bitcoin, Crypto, Solana, Ethereum, Gold, XRP), all neutral and non-dispute related, suggesting routine sponsor-level transitions without operational discord. Positive executive appointments dominate (e.g., ex-Macy's CEO at Signet, biotech veteran at iBio, Precision Castparts CFO at CPS Tech), with sentiments positive in 12/50 filings, contrasting rare negative cases like Cyber Enviro-Tech CFO exit. Retention incentives (Timken GC to 2028) and performance RSUs (Sonic Automotive) highlight management conviction, while planned retirements (FHLB Boston CEO, WEC Chairman) show orderly succession. No explicit YoY/QoQ financial declines noted, but high withheld votes in gaming (Boyd 20M+ for one director) and REITs (Invitation Homes 50M+) flag potential shareholder dissent; overall, bullish stability with alpha in leadership upgrades across retail, biotech, fintech.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 08, 2026

Across 50 filings from May 8, 2026, focused on USA board room changes, a dominant theme is robust shareholder approval at annual meetings for 15+ companies (e.g., 90%+ FOR votes in Edwards Lifesciences, Ally Financial, averaging 88-99% support), signaling strong governance alignment amid board refreshes via retirements and elections. C-suite transitions cluster in finance roles, with 12 CFO/CAO changes (e.g., identical swaps at 6 Franklin ETFs, Playtika's permanent CFO appointment), mostly neutral but positive for experienced hires like CPS Technologies' Chris Fraser from Berkshire subsidiary. Positive sentiments prevail (24/50 filings), driven by high-profile board adds (Signet Jewelers' ex-Macy's CEO, iBio's biotech MD, Butterfly Network's medtech vet) and promotions (HealthStream COO), contrasting isolated negative signals like CFO resignations at Cyber Enviro-Tech and Robinhood CTO separation. No explicit YoY financial declines noted, but high withhold votes (e.g., 20M+ at Boyd Gaming, 54M at Invitation Homes) flag pockets of dissent; equity grants and retention deals (e.g., Timken EVPG&C, Sonic Automotive PSUs) indicate retention focus. Portfolio-level pattern: small-cap/ETF churn vs large-cap stability suggests sector rotation opportunities; implications include enhanced strategic execution from retail/biotech expertise amid no reported guidance cuts.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 07, 2026

Across 15 DEF 14A filings dated May 7, 2026, proxy season reveals a cluster of 12 annual/special meetings scheduled June 16-23, 2026, primarily for routine director elections (14/15 filings), say-on-pay advisory votes (9/15), auditor ratifications (9/15), and equity incentive plan approvals/amendments (4/15), signaling standard governance focus with no widespread financial declines disclosed. High insider ownership stands out in Capstone Holding (39.29% by directors/officers, CEO 21.12%/26.77% voting), indicating strong alignment, while positive transformation narratives in Designer Brands (inventory productivity, profitability gains despite tariffs) and Okta (AI agent era shift, board refresh) contrast neutral/mixed sentiment elsewhere. No explicit YoY/QoQ revenue or margin declines noted across filings, but governance risks emerge in Wave Life Sciences' redomiciliation (75% approval threshold, shareholder rights changes) and equity dilutions in CXApp/SurgePays (20%+ share issuances). Fund-heavy filings (6/15) show trustee elections post-acquisitions with continuity assurances. Portfolio implication: monitor June vote outcomes for governance catalysts, favoring high-ownership names like Capstone for conviction plays amid low-materiality routines.

15 high priority 15 total filings
· daily

US Executive Officer Management Changes SEC — May 07, 2026

Across 40 filings in the USA Executive & Director Changes stream (May 7, 2026), a dominant theme is proactive leadership transitions, with 12 CFO/controller-related changes (e.g., ITT interim CFO, Pagaya CFO succession, Shake Shack new CFO) and 8 new executive/director appointments signaling strategic refreshes amid growth phases. Period-over-period trends show mixed financial health: 7/12 companies with financials reported YoY revenue growth averaging +8% (e.g., Pagaya +10%, Nature's Sunshine +9%, Perdoceo +4.1%), but impairments/losses in energy/biotech (Ring $220M net loss, Arcturus -93% revenue) and margin contractions (Pagaya -19bps FRLPC). AGM outcomes were overwhelmingly positive (15/15 passed all proposals, avg >90% support), affirming governance stability. Capital allocation leans shareholder-friendly with dividends (Perdoceo $0.15/share), buybacks (Post $600M new auth), and ESPPs (Rogers, Telos). Portfolio-level, bullish signals from guidance raises (Pagaya FY GAAP net $110-160M) and insider-aligned comp (SenesTech CEO 5% equity) outweigh neutral departures, but vague filings (Power Integrations, STERIS) flag opacity risks. Implications: Opportunities in leadership-upgraded growth names (AudioEye, Proto Labs), caution on interim-heavy transitions.

40 high priority 40 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 07, 2026

Across 39 US SEC filings focused on board room changes from May 7, 2026, a dominant theme is elevated C-suite turnover, particularly CFO and executive roles, with 12 instances of departures, appointments, or interim placements (e.g., ITT, Pagaya, Shake Shack, multiple New Mountain entities), signaling potential strategic shifts amid mixed financial performances. Annual general meetings (AGMs) in 12 companies showed overwhelming approvals for directors, auditors, and incentive plans (e.g., Rogers, Telos, Pediatrix), reflecting strong shareholder confidence and board stability. Period-over-period trends reveal robust revenue growth in 7 firms averaging +11% YoY (Pagaya +10%, Nature's Sunshine +9%, AudioEye quadrupling since 2019), but margin pressures in others (Pagaya FRLPC -19 bps YoY, Ring Energy impairments) and biotech trial mixed results (enGene 54% CR but 25% at 12 months). Positive capital allocation includes Post Holdings' $600M buyback authorization and multiple ESPP approvals; forward guidance raised in Pagaya (FY2026 Adj EBITDA $420-460M) and affirmed in Post ($1.55-1.58B). Portfolio-level patterns highlight hospitality/data (Target Hospitality), biotech volatility (enGene, Arcturus), and energy mixed ops (Ring, Peabody), with actionable implications for monitoring leadership transitions as catalysts for outperformance or distress.

39 high priority 39 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 06, 2026

Across 11 DEF 14A proxy statements, overarching themes include routine director elections (10/11 filings), advisory say-on-pay votes on 2025/2026 executive compensation (7/11), auditor ratifications (8/11), and governance enhancements like officer exculpation amendments and equity plan expansions, with all AGMs clustered in June 2026. Period-over-period trends are sparse but highlight exceptional performance at Williams Sonoma (FY2025 record $8.84 EPS, 18.1% op margin, 3.5% comp brand revenue growth, 241% 3yr TSR vs peer 22%) and BJ's Wholesale (100% director attendance, zero insider policy violations), contrasting Lithium Americas' mixed lithium price declines to June 2025 lows followed by H2 recovery amid Thacker Pass funding ($905.6M cash, 93% engineering complete). No widespread margin compression or revenue declines noted; instead, positive governance and project milestones dominate. Portfolio-level patterns show strong consumer/retail conviction (2/11 with positive sentiment), routine fund/BDC filings (4/11 neutral), and dilution risks from equity plans (e.g., Fluent +52% shares). Market implications: High approval odds for proposals boost stability, but watch comp votes and virtual AGMs for shareholder sentiment signals ahead of summer catalysts.

11 high priority 11 total filings
· daily

US Executive Officer Management Changes SEC — May 06, 2026

Across 34 filings in the USA Executive & Director Changes stream (May 6, 2026), leadership transitions dominate with 18 CEO/CFO/COO promotions or appointments (e.g., Orrstown, General Mills, Birchtech), 10 departures/retirements (e.g., Anavex CEO, Energy Recovery CEO/CFO), and 6 annual meetings with strong director election support (avg 95%+ for/approval). Period-over-period trends show mixed financials where disclosed: Energy Recovery revenue +20% YoY but gross margins -2750 bps to 27.8%; eHealth revenue -22% YoY but Medicare margins +700 bps to 41%; no broad insider trading but capital allocation positives like Energy Recovery's $25M buyback and Carvana's 1:5 split. Positive sentiment in 12/34 (35%) centers on experienced hires/promotions enhancing strategy (e.g., Hamilton Insurance, Wiley AI focus), while mixed/negative in 7/34 flag risks from sudden exits (Regenerex CFO termination, Anavex CEO departure with 10-Q delay). Portfolio-level pattern: orderly transitions signal continuity in financials/insurance (e.g., Orrstown, RenaissRe), but biotech/healthcare shows churn (Anavex, Bionano, Actuate with going concern). Implications: Bullish for stable firms with internal promotions; monitor biotech for disruption risks amid M&A/innovation catalysts.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 06, 2026

Across 34 filings from May 6, 2026, USA boardroom changes reveal high executive turnover with 12 CEO/CFO transitions (7 appointments, 5 departures), predominantly neutral sentiment (18/34) but tilting positive in financials/insurance (e.g., 95%+ AGM approvals in 6 cases). Period-over-period trends show mixed financial health: revenue growth in 4 firms (Energy Recovery +20% YoY, OEM +65%; eHealth Medicare margins +700bps despite -22% rev; Flutter FY25 +17%) contrasted by sharp declines (Energy Recovery gross margins -2750bps, eHealth net loss widening). Critical developments include sudden CFO terminations/suspensions (Regenerex, Bright Mountain) and interim leadership in biotechs (Anavex, Bionano), signaling potential governance risks amid 3 10-Q extensions/delays. Portfolio-level patterns: Planned retirements/successions (8 cases) outnumber contentious exits (4), with strong shareholder support at AGMs (avg 95%+ approval rates); insurance/financial sectors show board strengthening via experienced adds, while biotechs face leadership voids amid cash concerns. Capital allocation leans retention-focused (e.g., Energy Recovery $25M buyback, comp hikes), but M&A/integration ties (Flora, International Endeavors) flag strategic shifts. Implications: Opportunities in stable transitions, risks in interim-heavy biotechs.

34 high priority 34 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 05, 2026

Across 12 DEF 14A proxy filings dated around May 5, 2026, overarching themes include routine annual meetings for director elections (9/12), auditor ratifications (10/12), say-on-pay advisory votes (5/12), and equity incentive plan approvals, alongside special actions like share increases (Orgenesis, FibroBiologics), SPAC deadline extensions (Range Capital), reverse stock splits (Beyond Air), and reincorporations (Sonoma). Key period-over-period trends: CrowdStrike's FY2026 revenue +22% YoY to $4.81B, ARR +24% YoY to $5.25B, FCF margin 26%; FONAR exec comp down 21% YoY for CEO to $295k while flat for another; Range Capital trust +5.6% to $121.9M from post-IPO $115.6M. Critical developments: delisting risks (Beyond Air), dilution proposals (4/12 filings), and strong governance signals (Workday). Market implications: heightened dilution risks in biotechs/SPACs signal bearish near-term pressure, while SaaS leaders like CrowdStrike show portfolio-level growth outperformance; neutral sentiment dominates (8/12), but vote outcomes could drive volatility ahead of summer meetings.

12 high priority 12 total filings
· daily

US Executive Officer Management Changes SEC — May 05, 2026

Across 36 filings in the USA Executive & Director Changes stream, a dominant theme is high executive turnover, particularly in finance roles (CFOs, controllers, accounting officers in 12 companies including Atlantic American, Kimberly-Clark, Core Scientific, CF Industries, Genesco, Portillo's), with 18 appointments and 14 departures, often neutral but featuring experienced hires signaling continuity. Embedded Q1/FY2026 earnings show mixed revenue trends (avg +3.5% YoY across 15 reporting firms, but declines in 7 like Energizer -3%, FTC Solar -17%, Primoris -5.4%), offset by margin expansions (e.g., Energizer +360bps, Emerson +320bps) and reaffirmed/raised guidance in 10 cases. Positive sentiments dominate leadership adds (e.g., Integra, iAnthus, CF Industries), while negatives cluster around disputes (B&G Foods). Portfolio-level: Margin resilience amid soft volumes; capital returns strong ($500M Klaviyo buyback, $2.2B Emerson). Implications: Opportunities in experienced leadership turnarounds, risks in finance churn; watch catalysts like earnings calls.

36 high priority 36 total filings